• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PGRP-S通过与TTC1相互作用,经由丝裂原活化蛋白激酶/细胞外信号调节激酶(MAPK/ERK)信号通路促进肝细胞癌进展。

PGRP-S promotes hepatocellular carcinoma progression via MAPK/ERK pathway by interaction with TTC1.

作者信息

Zhu Huifang, Feng Shuang, Lv Sizhen, Zhao Di, Chang Xuanhe, Fan Shangqian, Wang Xia, Qian Xinlai

机构信息

Department of Pathology, The Third Affiliated Hospital of Xinxiang Medical University, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan, China.

The First Bethune Clinical Medical College of Ji Lin University, Changchun, Jilin, China.

出版信息

Sci Rep. 2025 Aug 4;15(1):28367. doi: 10.1038/s41598-025-12160-x.

DOI:10.1038/s41598-025-12160-x
PMID:40760131
Abstract

Abnormal expression of PGRP-S plays an important role in the development and progression of hepatocellular carcinoma (HCC), although the mechanism has remained elusive. In this study, we aimed to investigate the biological function and potential mechanism of PGRP-S in HCC. We found that PGRP-S was upregulated in HCC tissues compared to adjacent tissues. The increased expression of PGRP-S correlated with the differentiation and lymph node metastasis of HCC. PGRP-S obviously promoted HCC cell proliferation, migration and invasion in vitro. In vivo nude mouse models showed that PGRP-S enhanced tumor growth and pulmonary metastasis. Mechanistically, PGRP-S interacted with TTC1 and activated MAPK/ERK pathway, leading to HCC cell proliferation, migration and invasion. Therfore, our conclusion is PGRP-S promotes HCC cell proliferation, migration and invasion by activating MAPK/ERK pathway, which provides a new potential strategy for HCC treatment by targeting PGRP-S-TTC1 axis.

摘要

尽管机制尚不清楚,但肽聚糖识别蛋白-S(PGRP-S)的异常表达在肝细胞癌(HCC)的发生和发展中起重要作用。在本研究中,我们旨在探讨PGRP-S在HCC中的生物学功能和潜在机制。我们发现,与癌旁组织相比,PGRP-S在HCC组织中上调。PGRP-S表达增加与HCC的分化和淋巴结转移相关。PGRP-S在体外明显促进HCC细胞增殖、迁移和侵袭。体内裸鼠模型显示,PGRP-S增强肿瘤生长和肺转移。机制上,PGRP-S与TTC1相互作用并激活MAPK/ERK通路,导致HCC细胞增殖、迁移和侵袭。因此,我们的结论是PGRP-S通过激活MAPK/ERK通路促进HCC细胞增殖、迁移和侵袭,这为通过靶向PGRP-S-TTC1轴治疗HCC提供了一种新的潜在策略。

相似文献

1
PGRP-S promotes hepatocellular carcinoma progression via MAPK/ERK pathway by interaction with TTC1.PGRP-S通过与TTC1相互作用,经由丝裂原活化蛋白激酶/细胞外信号调节激酶(MAPK/ERK)信号通路促进肝细胞癌进展。
Sci Rep. 2025 Aug 4;15(1):28367. doi: 10.1038/s41598-025-12160-x.
2
Non-canonical activation of MAPK signaling by the lncRNA ASH1L-AS1-encoded microprotein APPLE through inhibition of PP1/PP2A-mediated ERK1/2 dephosphorylation in hepatocellular carcinoma.在肝细胞癌中,长链非编码RNA ASH1L-AS1编码的微小蛋白APPLE通过抑制PP1/PP2A介导的ERK1/2去磷酸化对MAPK信号通路进行非经典激活。
J Exp Clin Cancer Res. 2025 Jul 11;44(1):200. doi: 10.1186/s13046-025-03465-w.
3
Long non-coding RNA LNC-POTEM-4 promotes HCC progression via the LNC-POTEM-4/miR-149-5p/Wnt4 signaling axis.长非编码 RNA LNC-POTEM-4 通过 LNC-POTEM-4/miR-149-5p/Wnt4 信号轴促进 HCC 进展。
Cell Signal. 2024 Dec;124:111412. doi: 10.1016/j.cellsig.2024.111412. Epub 2024 Sep 13.
4
C-Myc-activated FKBP4 promotes hepatocellular carcinoma cell proliferation and invasion by regulating the PHLPP1/AKT pathway.C-Myc激活的FKBP4通过调节PHLPP1/AKT通路促进肝癌细胞增殖和侵袭。
Pathol Res Pract. 2025 Aug;272:156119. doi: 10.1016/j.prp.2025.156119. Epub 2025 Jul 9.
5
High glucose facilitates hepatocellular carcinoma cell proliferation and invasion via WTAP-mediated HK2 mRNA stability.高糖通过WTAP介导的HK2 mRNA稳定性促进肝癌细胞增殖和侵袭。
Mol Cell Biochem. 2025 Mar 3. doi: 10.1007/s11010-025-05235-w.
6
ARL8B promotes hepatocellular carcinoma progression and inhibits antitumor activity of lenvatinib via MAPK/ERK signaling by interacting with RAB2A.ARL8B 通过与 RAB2A 相互作用,激活 MAPK/ERK 信号通路促进肝癌进展并抑制仑伐替尼的抗肿瘤活性。
Cell Signal. 2024 Dec;124:111470. doi: 10.1016/j.cellsig.2024.111470. Epub 2024 Oct 15.
7
IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.IGF2 通过表观遗传机制在肝细胞癌中上调,并且是实验模型中可操作的癌基因产物。
Gastroenterology. 2016 Dec;151(6):1192-1205. doi: 10.1053/j.gastro.2016.09.001. Epub 2016 Sep 7.
8
MARCH5 promotes hepatocellular carcinoma progression by inducing p53 ubiquitination degradation.MARCH5 通过诱导 p53 泛素化降解促进肝癌进展。
J Cancer Res Clin Oncol. 2024 Jun 11;150(6):303. doi: 10.1007/s00432-024-05782-7.
9
MicroRNA-34c-3p promotes cell proliferation and invasion in hepatocellular carcinoma by regulation of NCKAP1 expression.微小RNA-34c-3p通过调控NCKAP1表达促进肝细胞癌的细胞增殖和侵袭。
J Cancer Res Clin Oncol. 2017 Feb;143(2):263-273. doi: 10.1007/s00432-016-2280-7. Epub 2016 Oct 4.
10
Knockdown of LncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma.长链非编码RNA ANRIL的敲低通过调节miR-122-5p的表达抑制肝癌细胞的增殖、转移和侵袭。
J Cancer Res Clin Oncol. 2018 Feb;144(2):205-214. doi: 10.1007/s00432-017-2543-y. Epub 2017 Nov 10.

本文引用的文献

1
ARL8B promotes hepatocellular carcinoma progression and inhibits antitumor activity of lenvatinib via MAPK/ERK signaling by interacting with RAB2A.ARL8B 通过与 RAB2A 相互作用,激活 MAPK/ERK 信号通路促进肝癌进展并抑制仑伐替尼的抗肿瘤活性。
Cell Signal. 2024 Dec;124:111470. doi: 10.1016/j.cellsig.2024.111470. Epub 2024 Oct 15.
2
Targeting PGLYRP1 promotes antitumor immunity while inhibiting autoimmune neuroinflammation.靶向 PGLYRP1 既能促进抗肿瘤免疫,又能抑制自身免疫性神经炎症。
Nat Immunol. 2023 Nov;24(11):1908-1920. doi: 10.1038/s41590-023-01645-4. Epub 2023 Oct 12.
3
STUB1/CHIP: New insights in cancer and immunity.
STUB1/CHIP:癌症与免疫的新见解。
Biomed Pharmacother. 2023 Sep;165:115190. doi: 10.1016/j.biopha.2023.115190. Epub 2023 Jul 26.
4
KEGG for taxonomy-based analysis of pathways and genomes.KEGG 用于基于分类的途径和基因组分析。
Nucleic Acids Res. 2023 Jan 6;51(D1):D587-D592. doi: 10.1093/nar/gkac963.
5
Short Peptides of Innate Immunity Protein Tag7 Inhibit the Production of Cytokines in CFA-Induced Arthritis.天然免疫蛋白 Tag7 的短肽抑制 CFA 诱导关节炎细胞因子的产生。
Int J Mol Sci. 2022 Oct 17;23(20):12435. doi: 10.3390/ijms232012435.
6
N-Terminal Peptide of PGLYRP1/Tag7 Is a Novel Ligand for TREM-1 Receptor.PGLYRP1/Tag7 的 N 端肽是 TREM-1 受体的新型配体。
Int J Mol Sci. 2022 May 20;23(10):5752. doi: 10.3390/ijms23105752.
7
Metabolic regulation of the cancer-immunity cycle.肿瘤免疫循环的代谢调控
Trends Immunol. 2021 Nov;42(11):975-993. doi: 10.1016/j.it.2021.09.002. Epub 2021 Oct 2.
8
Combination strategies to maximize the benefits of cancer immunotherapy.联合策略以最大化癌症免疫疗法的益处。
J Hematol Oncol. 2021 Sep 27;14(1):156. doi: 10.1186/s13045-021-01164-5.
9
Epigenetics in hepatocellular carcinoma.肝细胞癌中的表观遗传学。
Semin Cancer Biol. 2022 Nov;86(Pt 3):622-632. doi: 10.1016/j.semcancer.2021.07.017. Epub 2021 Jul 26.
10
Peptidoglycan Recognition Protein 1 Attenuates Atherosclerosis by Suppressing Endothelial Cell Adhesion.肽聚糖识别蛋白 1 通过抑制内皮细胞黏附来减轻动脉粥样硬化。
J Cardiovasc Pharmacol. 2021 Oct 1;78(4):615-621. doi: 10.1097/FJC.0000000000001100.